Physician profile
Melinda Wright
NPI 1861770380
$1,089.93
in general payments reported to CMS, 2019-2025
23 companies · $71.61 in 2025
The $71.61 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $396 · 2023: $179 · 2024: $198 · 2025: $71.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $166.43 | 2021-2023 | Repatha |
| Novo Nordisk INC | $163.56 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $134.85 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $68.33 | 2022-2024 | Breztri, Farxiga |
| Exact Sciences Corporation | $62.52 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $59.03 | 2023-2024 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company Ltd. | $57.21 | 2022 | |
| Amarin Pharma, INC. | $50.96 | 2021 | |
| Pfizer INC. | $46.74 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $32.62 | 2022-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $31.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.04 | 2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $23.72 | 2021 | |
| Abbott Laboratories | $21.94 | 2024 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $19.14 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $16.85 | 2022 | |
| Neurocrine Biosciences, INC. | $16.23 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.85 | 2021 | |
| Merck Sharp & Dohme LLC | $15.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.14 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.98 | 2023 | Gvoke Hypopen |
| Antares Pharma, INC. | $14.48 | 2023 | Tlando, Xyosted, Nocdurna |
| Horizon Therapeutics Plc | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.